Internet Pioneer In...
Health Care: Drugs
Alkermes PLC (ALKS: NASDAQ)
$15.12 -0.50 | -3.20%
06/01/12 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 15.12 |
| 52 Week High | 20.00 |
| 52 Week Low | 13.48 |
| Avg. Daily Vol. (Mil) | 1.32 |
| Beta (3 year) | 0.77 |
| Share Related Items | |
| Mkt Cap (Mil) | 1,969.25 |
| Shares Out (Mil) | 130.24 |
| Float (Mil) | 82.67 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 3.20 |
| Current Ratio | 3.80 |
| LT Debt/ Equity | 0.52 |
| Total Debt / Equity | 0.52 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 5.05 |
| Price/Book | 2.31 |
| Price/Cash Flow | -98.50 |
| Per Share Data | |
| Earnings | -0.99 |
| Sales | 2.99 |
| Book Value | 6.56 |
| Cash Flow | -0.15 |
| Business Summary | |
|---|---|
| Alkermes, Inc. is a biotechnology company committed to developing innovative medicines to improve patients' lives. | |
| General Information | |
| Treasury Building
Lower Grand Canal Street Dublin, 2 |
|
| www.alkermes.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 1200 | |
| CEO: Richard F. Pops | |
| Short Interest | |
| Current Month (Mil) | 6.92 |
| Previous Month (Mil) | 6.95 |
| Short Interest Ratio (Days) | 7.10 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -7.90 |
| Return on Investments | -8.80 |
| Profitability | |
| Gross Margin | 73.10 |
| EBIT Margin | -22.10 |
| Profit Margin | -29.10 |
Portfolios with ALKS
- Portfolio NameUser Type
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- UserInvestments
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorBreakout Stocks Of The Week...
- Usergterryburns
- Usermitetwo Portfolio 1
- ContributorBreakout Stocks Of The Week...
- Contributor10 Biotech Stocks Facing FD...
Latest ALKS Headlines from TheStreet
- Cramer's 'Mad Money' Recap: Housing Comeback 05.10.12 | 08:05 pm
- 5 Stocks Insiders Love Right Now 05.02.12 | 11:05 am
- 8 Stocks Rising on Monster Volume 03.28.12 | 12:03 pm
- Insiders Trading TZYM, ALKS, CAKE 03.15.12 | 08:03 am
- The Curse of Amylin's Diabetes Drug Approval 02.06.12 | 08:02 am
- PharMerica, Amylin: After-Hours Trading 01.27.12 | 06:01 pm
- Third Time's The Charm for Approval of Amylin Diabetes Drug 01.27.12 | 03:01 pm
- 7 Stocks Rising on Huge Volume 01.25.12 | 02:01 pm
- UBS: 6 Specialty Pharma Picks to Watch 01.21.12 | 07:01 am
- Biotech Lessons Learned From JPM 2012 01.13.12 | 06:01 am
Press Releases for ALKS
- Alkermes’ Corporate Presentation To Be Webcast At Two Upcoming Conferences - Business Wire 05.31.12 | 07:05 am
- Alkermes Announces Results From Phase 2 Study Of ALKS 37 For Treatment Of Opioid-Induced Constipation - Business Wire 05.30.12 | 04:05 pm
- Alkermes Presents Positive Clinical Data Of ALKS 5461 At 52nd Annual New Clinical Drug Evaluation Unit Meeting - Business Wire 05.29.12 | 04:05 pm
- Alkermes Plc Completes Secondary Offering Of 24,150,000 Ordinary Shares Held By Elan - Business Wire 03.13.12 | 11:03 am
- Alkermes Plc Prices Secondary Offering Of 21,000,000 Ordinary Shares Held By Elan - Business Wire 03.08.12 | 09:03 am
- Alkermes Plc Announces A Secondary Offering Of 13,900,000 Ordinary Shares Held By Elan - Business Wire 03.07.12 | 04:03 pm
- Alkermes Appoints Mark Stejbach As Chief Commercial Officer - Business Wire 03.05.12 | 07:03 am
- Alkermes’ Corporate Presentation To Be Webcast At The Cowen & Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 04:02 pm
- Alkermes Files Resale Shelf Registration In Connection With Elan Shareholder Agreement - Business Wire 02.16.12 | 04:02 pm
- BYDUREONâ¢, First And Only Once-Weekly Type 2 Diabetes Treatment, Now Available In U.S. Pharmacies - PR Newswire 02.13.12 | 08:02 am
Partner Headlines for ALKS
- Healthcare Biz Recap: Teva's Counterfeit Problem, Hopes for Bristol-Myers - Wall St. Cheat Sheet 05.30.12 | 07:05 am
- Alkermes Earnings Call Insights: Adjusted EBITDA, VIVITROL - Wall St. Cheat Sheet 05.29.12 | 01:05 pm
- 9 High-Liquidity Mid Caps Poised For Growth - Seeking Alpha 05.28.12 | 08:05 am
- Long Undervalued, Is Alkermes Still A Bargain? - Seeking Alpha 03.30.12 | 09:03 am
- Kinetics Hedge Fund's Top Undervalued Picks - Seeking Alpha 03.23.12 | 05:03 pm
- Elan Sells 76% Stake in Alkermes - Analyst Blog - Zacks 03.16.12 | 05:03 pm
- Alkermes Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by Elan - Benzinga 03.07.12 | 04:03 pm
- Bydureon Physician Survey: Results Yield Insight Into Launch Trajectory - Seeking Alpha 02.22.12 | 08:02 am
- The Zacks Analyst Blog Highlights: Charles Schwab, E*TRADE Financial, TD Ameritrade Holding, Amylin Pharmaceuticals and Alkermes plc - Press Releases - Zacks 02.16.12 | 09:02 am
- Analyzing Friday's Noteworthy Insider Buys And Sells - Seeking Alpha 02.12.12 | 07:02 am
